Are Fund Managers Better Than Their Funds?
For investors still cringing at their IRAs, 401(k)s or taxable mutual funds and exchange-traded funds, are you ready to take a chance on the companies that have brought you so many unhappy returns?
04:51PM 04/20/09
Can Regional Brokers Keep Outperforming?
The regionals may not have as much recognition as the mammoth securities firms, but they won't be receiving as many unwanted headlines either.
10:49AM 02/16/09
Wyeth Deal's Big, but Pfizer Still Needs a Blockbuster
If Pfizer's looking for the next Lipitor, it probably hasn't found it with the acquisition of Wyeth.
04:43PM 01/26/09
Cosmetic Surgery Stocks Keep Stiff Upper Lip
Allergan, Mentor and Medicis have struggled in the past year, but if the economy improves, share prices could, too.
05:05PM 10/28/08
For Abbott, Diversity Remains Paramount
When it comes to investing in big pharmaceutical stocks, it's hard to top this company, especially as its peers continue to suffer.
01:06PM 08/21/08
Legal Questions Still Dogging Wyeth
The company continues to wrestle with the dilemma surrounding the drugs Premarin, Prempro and Premphase. Plaintiffs' lawyers have filed approximately 5,400 lawsuits.
12:37PM 07/21/08
Baxter International Hiding in Plain Sight
In the past five years, its stock has more than tripled, easily outperforming the S&P 500 and the Amex Index of large drug stocks. Is anyone paying attention?
06:59AM 07/01/08
Generic-Drug Stocks Still Under the Weather
Shares of most major generic-drugmakers have traded below the S&P 500 for the 12 months ended May 23, and that index was off nearly 10%.
01:40PM 06/05/08
Need Defense? Think Medical Supplies
Companies such as C.R. Bard and Becton Dickinson might not be the most glamorous names, but their slow and steady performances may win the race.
06:44AM 04/11/08
The Real Winners of Drug Experimentation
The companies that supply the tools needed for pharma research and development often profit no matter the success of a drug trial.
06:59AM 04/03/08


RSS Feed
Connect with TheStreet